Evolus Inc (NASDAQ:EOLS) – Research analysts at SunTrust Banks dropped their FY2019 earnings per share estimates for Evolus in a research report issued on Monday, November 19th. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings of ($4.56) per share for the year, down from their previous estimate of ($2.01). SunTrust Banks currently has a “Buy” rating and a $27.00 target price on the stock. SunTrust Banks also issued estimates for Evolus’ FY2020 earnings at ($1.34) EPS and FY2021 earnings at $1.32 EPS.

Several other equities analysts have also weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 price target on shares of Evolus in a research note on Monday, September 17th. Zacks Investment Research lowered Evolus from a “hold” rating to a “sell” rating in a research note on Tuesday, September 25th. Finally, JMP Securities restated an “outperform” rating and issued a $35.00 price target on shares of Evolus in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $30.40.

Shares of Evolus stock opened at $14.70 on Wednesday. Evolus has a twelve month low of $6.75 and a twelve month high of $39.50. The stock has a market capitalization of $377.49 million and a P/E ratio of -54.44.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.09).

A number of large investors have recently bought and sold shares of EOLS. SG Americas Securities LLC acquired a new position in shares of Evolus during the 2nd quarter worth approximately $108,000. Wells Fargo & Company MN boosted its holdings in shares of Evolus by 860.3% during the 3rd quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after purchasing an additional 5,325 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Evolus by 761.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after purchasing an additional 5,794 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Evolus by 51.2% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock worth $228,000 after purchasing an additional 4,151 shares during the last quarter. Finally, Man Group plc acquired a new position in shares of Evolus during the 3rd quarter worth approximately $232,000. Institutional investors own 15.18% of the company’s stock.

In other news, insider Michael M. Jafar acquired 12,800 shares of the business’s stock in a transaction on Friday, September 14th. The stock was bought at an average cost of $20.83 per share, for a total transaction of $266,624.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Evolus Company Profile

Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.